VISCHER advises Swiss biotech firm and Merck KGaA spin-off Vaximm AG, in Basel, in a private financing round totaling CHF 7.8 million from new and existing investors. BB Biotech Ventures and Merck KGaA were joined by new investors Sunstone Capital, Merck Serono Ventures and BioMedPartners. The Company is developing an investigational oral T-cell vaccine that is designed to elicit an immune response against vascular endothelium growth factor receptor-2 (VEGFR-2), a well characterized target for anti-angiogenic intervention. VISCHER led by Matthias Staehelin with Laura Rey advises the Company and existing investors.